|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previous suggested that PAR-2 and CRTh2 expression on specific peripheral blood cell subtypes may be biomarkers of asthma severity.
|
31168305 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition to its role in allergy and asthma, the role of Crth2 in the resolution of inflammation, to mediate the proresolving functions of endogenous CyPGs, is not well understood.
|
31518163 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This explains the design of highly selective compounds with innate abilities to antagonize PGD2-CRTh2 interactions and prevent pro-inflammatory allergies such as rhinitis and uncontrolled asthma.
|
31538888 |
2019 |
|
Asthma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As in literature, azaindole is a very potent moiety, its derivatives displayed a number of biological activities such as kinase inhibitors, cytotoxic agents, anti-angiogenic activity, CRTh2 receptor antagonists, melanin agonists, nicotine agonists, effectiveness in alzheimer disease, cytokinin analogs, Orai inhibitors in asthma and chemokine receptor- 2 (CCR2) antagonists.
|
30264679 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, a number of CRTH2 antagonists are under clinical investigation, and one compound, fevipiprant, has advanced to phase 3 clinical trials for asthma.
|
30220562 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRTH2 antagonist monotherapy can safely improve lung function and quality of life, and reduce asthma exacerbations and SABA use in asthmatics.
|
30413187 |
2018 |
|
Asthma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further optimization resulted in the identification of the preclinical candidate 4-(cyclopropyl((3<i>aS</i>,9<i>R</i>,9<i>aR</i>)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3<i>a</i>,4,9,9<i>a</i>-hexahydro-1<i>H</i>-cyclopenta[<i>b</i>]quinolin-9-yl)amino)-4-oxobutanoic acid (<b>15c</b>, <b>MK-8318</b>) with potent and selective CRTh2 antagonist activity and a favorable PK profile suitable for once daily oral dosing for potential treatment of asthma.
|
30034600 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostaglandin D2 (PGD2) signals through PGD2 receptor 2 (DP2, also known as CRTH2) on type 2 effector cells to promote asthma pathogenesis; however, little is known about its role during respiratory syncytial virus (RSV) bronchiolitis, a major risk factor for asthma development.
|
29743346 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This systematic review will increase the understanding of the application of CRTH2 antagonists in patients with asthma, which may help to establish and identify specific gaps in the evidence informing a future agenda for asthma research, policy and practice.
|
29678990 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent clinical trials have demonstrated that targeting inflammatory pathways orchestrated through IL-4, IL-5, IL-13, and the prostaglandin receptor CRTH2 is potentially highly effective in adult asthma.
|
29427987 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on current data we propose that blocking CRTH2 might be a potential therapeutic approach to numerous conditions beyond classical allergic diseases and asthma.
|
28818625 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To ealuate the efficacy, safety, and pharmacokinetics of BI 671800, a CRTH2 antagonist, when added to inhaled corticosteroid therapy in adult patients with symptomatic asthma.
|
28234053 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data support further investigation of CRTH2 antagonists for the treatment of asthma.
|
28609567 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel small molecule drugs, such as CRTH2 receptor antagonists, PDE<sub>4</sub> inhibitors, protein kinase inhibitors and nonsteroidal glucocorticoid receptor agonists and 'off-label' use of licensed drugs, such as macrolides and statins are under investigation for asthma, although their effectiveness in clinical practice is not established.
|
28099820 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A number of CRTH2/PGD<sub>2</sub> receptor antagonists have been investigated in asthma and allergic diseases.
|
28612233 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current treatment options for severe asthma are inadequate and therapeutic antibody-mediated depletion of CRTh2-expressing cells represents a promising new therapeutic strategy.
|
27103662 |
2016 |
|
Asthma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Current treatment options for severe asthma are inadequate and therapeutic antibody-mediated depletion of CRTh2-expressing cells represents a promising new therapeutic strategy.
|
27103662 |
2016 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The D prostanoid receptor 2 (DP2; also known as chemoattractant receptor-homologous molecule expressed on TH2 cells) is implicated in the pathogenesis of asthma, but its expression within bronchial biopsy specimens is unknown.
|
25312757 |
2015 |
|
Asthma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Asthma exacerbations, poor asthma control, and TH2 inflammatory markers were associated with higher PGD₂, HPGDS, and CRTH2 levels.
|
23506843 |
2013 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein we present evidence that PGH(1) is a potent activator of the pro-inflammatory PGD(2) receptor CRTH2, an attractive therapeutic target to treat allergic diseases such as asthma and atopic dermatitis.
|
22442685 |
2012 |
|
Asthma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Considering the fact that eosinophil infiltration is prominent in the upper and lower airways of aspirin exacerbated respiratory disease (AERD) compared to aspirin-tolerant asthma (ATA) patients, we hypothesized that activation of eosinophils via dysregulation of the CRTH2 gene may play an important role and be an important marker for AERD.
|
19796209 |
2010 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic variations in chemoattractant receptor expressed on Th2 cells (CRTH2) is associated with asthma susceptibility in Chinese children.
|
18777142 |
2009 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation within CRTh2 modifies the development of allergic sensitization and asthma in a population of German children.
|
19392992 |
2009 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, genetic association studies have shown a positive linkage of the genetic polymorphisms in DP and CRTH2, with asthma phenotypes from specific ethnic backgrounds, further highlighting the importance of PGD(2) and its receptors in the pathophysiology of asthma.
|
18946232 |
2008 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation.
|
18757520 |
2008 |